Literature DB >> 11150284

Iris melanoma: risk factors for metastasis in 169 consecutive patients.

C L Shields1, J A Shields, M Materin, E Gershenbaum, A D Singh, A Smith.   

Abstract

OBJECTIVE: To identify risk factors that predict distant metastases of iris malignant melanoma.
DESIGN: Retrospective case series. PARTICIPANTS: The participants included 169 consecutive patients with microscopically confirmed iris malignant melanoma managed on the Oncology Service at Wills Eye Hospital between 1974 and 1999. MAIN OUTCOME MEASURES: The main outcome measure was the development of distant tumor metastasis. Cox proportional regression models were used to calculate the risk of eventual metastatic spread.
RESULTS: Of 1054 patients referred with suspicious iris melanocytic tumors (rule out malignant melanoma) over a 25-year period, 169 patients (16%) had microscopically proven iris melanoma, and the remainder (84%) had clinically diagnosed iris nevus. Of the patients with iris melanoma, the mean age at the time of diagnosis was 43 years (median, 45 years; range, 1-90 years). All patients were Caucasian. The mean tumor base was 6 mm (median, 5 mm; range, 1-17 mm), and mean tumor thickness was 2 mm (median, 2 mm; range, 1-4 mm). The mean number of clock hours of tumor involvement in the iris was four, tumor seeding on the iris was four, and tumor seeding into the anterior chamber angle was four. Extraocular extension was present in 10 eyes (6%). The tumor management consisted of local resection (iridectomy, iridocyclectomy, or iridocyclogoniectomy) in 102 patients (60%), enucleation in 51 (30%), plaque radiotherapy in 9 (5%), and observation in 7 patients (4%). Metastasis developed in nine patients (5%). Using Kaplan-Meier life table analysis, metastasis was found in 3% of patients at 5 years, 5% at 10 years, and 10% at 20 years. The clinical factors at initial evaluation predictive of eventual metastasis from iris melanoma included increasing age at diagnosis (P = 0.03), elevated intraocular pressure (P = 0.03), posterior tumor margin at angle or iris root (versus midzone) (P = 0.02), extraocular extension (P: = 0.02), and prior surgical treatment of the tumor elsewhere before referral (versus observation) (P = 0.006). The method of management (resection, radiotherapy, or enucleation) did not have an impact on metastasis.
CONCLUSIONS: Microscopically confirmed iris melanoma demonstrates distant metastasis in 5% of patients at 10 years follow-up. Metastases are more likely to develop in those patients who are older and show tumor features of iris root/angle location with elevated intraocular pressure and extraocular extension.

Entities:  

Mesh:

Year:  2001        PMID: 11150284     DOI: 10.1016/s0161-6420(00)00449-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  45 in total

Review 1.  [New treatment options for iridociliary tumors].

Authors:  J M Mor; K R Koch; V Kakkassery; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2019-04       Impact factor: 1.059

Review 2.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

3.  Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.

Authors:  Aline I Riechardt; Bettina Karle; Dino Cordini; Jens Heufelder; Volker Budach; Antonia M Joussen; Johannes Gollrad
Journal:  Strahlenther Onkol       Date:  2017-06-19       Impact factor: 3.621

4.  [Prominent iris tumor in the right eye].

Authors:  A C Hunold; S Dithmar; H E Voelcker; B Helmke
Journal:  Ophthalmologe       Date:  2008-11       Impact factor: 1.059

5.  Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma.

Authors:  M Tsimpida; J Hungerford; A Arora; V Cohen
Journal:  Eye (Lond)       Date:  2011-09-23       Impact factor: 3.775

6.  Optical Coherence Tomography Angiography Characteristics of Iris Melanocytic Tumors.

Authors:  Alison H Skalet; Yan Li; Chen D Lu; Yali Jia; ByungKun Lee; Lennart Husvogt; Andreas Maier; James G Fujimoto; Charles R Thomas; David Huang
Journal:  Ophthalmology       Date:  2016-11-14       Impact factor: 12.079

7.  Diffuse iris melanoma: Report of a case with review of the literature.

Authors:  Simon E Skalicky; Michael Giblin; R Max Conway
Journal:  Clin Ophthalmol       Date:  2007-09

8.  Baerveldt implant for secondary glaucoma due to iris melanoma.

Authors:  Annelie N Tan; Juliette G M M Hoevenaars; Carroll A B Webers; Bertil Damato; Henny J M Beckers
Journal:  Clin Ophthalmol       Date:  2010-05-06

9.  Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.

Authors:  Ahmed Rahmi; Hamid Mammar; Juliette Thariat; Gaelle Angellier; Joel Herault; Pierre Chauvel; Laurent Kodjikian; Philippe Denis; Jean Daniel Grange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-20       Impact factor: 3.117

10.  Ocular melanoma.

Authors:  Bertil E Damato; Sarah E Coupland
Journal:  Saudi J Ophthalmol       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.